LPL and metabolic syndrome: Indeed, inflammation and its cytokine-mediated changes in lipase activity (e.g., incretins, lipoprotein lipase, and cholesteryl ester transfer protein activity) potentially drive the alteration of atherogenic dyslipidemia [16, 17].